However, given the high level of genome instability and massive structural complexities in osteosarcoma our data argue that these tumors in particular should be analyzed using more comprehensive approaches combining next generation sequencing with immunohistochemistry to improve the detection of ATRX/DAXX pathway inactivation. This evidence concerns the gene ATRX and osteosarcoma.